An estimated 13 million people in the United States are currently being treated for thyroid disorders. Thirteen million more Americans may have undiagnosed thyroid dysfunction. Studies indicate that people with thyroid dysfunction face an increased risk for adverse cardiovascular, neuropsychiatric, and pregnancy outcomes.
To view the monograph, click here.

Based on Data Presented at a Continuing Medical Education Services Symposium during The Endocrine Society’s 85th Annual Meeting June 20, 2003, Philadelphia, Pennsylvania
To view the monograph, click here.

This newsletter provides background information and summaries of 3 lectures presented at the 12th Annual Meeting of the American Association of Clinical Endocrinologists (AACE) in San Diego, California on May 14,2003. The first lecture, presented by Stephanie L. Lee, MD, associate professor of medicine at Boston University School of Medicine and director of the Thyroid Disease Center at Boston Medical Center, discussed the reassessment of the thyroid stimulating hormone (TSH) reference range as a clinical measure for the diagnosis and treatment of thyroid disease. Bryan R.Haugen, MD, associate professor of medicine and pathology at University of Colorado School of Medicine and assistant chief of the Division of Endocrinology, Metabolism, and Diabetes at University of Colorado Health Sciences Center in Denver, Colorado, discussed the implications of using a narrower TSH reference range for thyroid function screening and management of thyroid disease. Peter A. Singer, MD, professor of clinical medicine at Keck School of Medicine of the University of Southern California and chief of clinical endocrinology and director of the Thyroid Diagnostic Center at University of Southern California Medical Center, Los Angeles, California, concluded the program by presenting a case study that described the utility of TSH measurements in the treatment and management of hypothyroidism in an elderly patient.
To view the complete report, click here.